Abstracts tagged "autoimmune diseases"

Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Munther Khamashta^1,2, Joan T. Merrill³, Victoria P. Werth^4,5, Richard Furie⁶, Kenneth Kalunian⁷, Gabor G. Illei⁸, Jorn Drappa⁸, Liangwei Wang⁸ and Warren Greth⁸, ¹Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, ²Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Philadelphia VA Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶North Shore-LIJ Health System, Lake Success, NY, ⁷UCSD School of Medicine, La Jolla, CA, ⁸MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
Abstract Number: 154 • 2013 ACR/ARHP Annual Meeting
Identification Of Autoimmune Disease Genes In Regions Under Selection In The Gullah African American Population Of South Carolina
Paula S. Ramos¹, Nathan Titus², Satria Sajuthi³, Jasmin Divers³, Yiqi Huang⁴, Uma Nayak⁵, Wei-Min Chen⁵, Kelly J. Hunt⁶, Diane L. Kamen⁷, Gary S. Gilkeson⁷, Jyotika K. Fernandes⁸, Ida J. Spruill⁸, W. Timothy Garvey⁹, Michèle M. Sale⁴ and Carl D. Langefeld³, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA, ⁵Public Health Sciences, University of Virginia, Charlottesville, VA, ⁶Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Medical University of South Carolina, Charleston, SC, ⁹Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Most autoimmune diseases (ADs) are more prevalent in specific ethnic groups. We hypothesize that one reason for the ethnic disparity may be an effect…
Abstract Number: 2655 • 2013 ACR/ARHP Annual Meeting
Therapeutic Effect Of β2GPI and Its Synthetic derivative Loaded Tolerogenic Dendritic Cells In Experimental Antiphospholipid Syndrome, Is Associated With miRNA 23b, 142-3p and 221 Expression and Tregs Upregulation
Miri Blank¹, Silvia S. Pierangeli², Honorio Torres-Aguilar³ and Yehuda Shoenfeld⁴, ¹Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³National Center for Blood Transfusion, Mexico City, Mexico, ⁴Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine, Tel-Aviv University,Tel-Aviv, Tel-Aviv, Israel
Background/Purpose: The importance of beta-glycoprotein I (beta2GPI)-specific CD4+ T cells in the development of pathogenic processes in patients with antiphospholipid syndrome (APS) and APS mice…
Abstract Number: 2555 • 2013 ACR/ARHP Annual Meeting
Development and Validation Of a Questionnaire To Screen For The Presence Of Autoimmune Disease
Alan Boroway¹, Aileen M. Davis², Carolina Landolt-Marticorena¹ and Joan E. Wither³, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Healthy family members of patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of developing autoimmune disease than the general population. …
Abstract Number: 2044 • 2013 ACR/ARHP Annual Meeting
Birth Outcomes In Childbearing Women Treated With Thiopurines: A Meta-Analysis
Zeinab F. Saleh¹, Raveendhara R. Bannuru², William F. Harvey² and Timothy E. McAlindon³, ¹Adult Rheumatology, Tufts Medical Center, Boston, MA, ²Rheumatology, Tufts Medical Center, Boston, MA, ³Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) are effective treatments for many rheumatic and autoimmune conditions. These medications have a category D classification from…
Abstract Number: 1914 • 2013 ACR/ARHP Annual Meeting
Patient and Physician Perspectives On Family Planning and Pregnancy Issues In Systemic Inflammatory Diseases: Mind The Gap!
Megan E. B. Clowse¹, Eliza Chakravarty², Daphnee S. Pushparajah³, Sarah Mertens³ and Caroline Gordon⁴, ¹Duke University Medical Center, Durham, NC, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Autoimmune and inflammatory diseases often affect women of reproductive age and can impact pregnancy outcomes. This patient (pt) group has important concerns about family…
Abstract Number: 1645 • 2013 ACR/ARHP Annual Meeting
Circulating CD4+CD161+ T Lymphocytes Are Increased In Seropositive Arthralgia Patients But Decreased In Patients With Newly Diagnosed Rheumatoid Arthritis
Paulina Chalan¹, Bart-Jan Kroesen², Kornelis S.M. van der Geest¹, Minke G. Huitema¹, Wayel H. Abdulahad³, Elisabeth Brouwer¹ and Annemieke M.H. Boots⁴, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Improved understanding of the immune events discriminating between seropositive arthralgia and clinical synovitis is of key importance in rheumatology research. Ample evidence suggests a…
Abstract Number: 1612 • 2013 ACR/ARHP Annual Meeting
Rituximab For Treatment Of Refractory Auto-Immune Hepatitis
Chadi Rakieh¹, Edward M. Vital², Paul Emery³ and Michael Martin¹, ¹Rheumatology, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ²Section of Musculoskeletal Disease, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ³Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom
Background/Purpose: Auto-immune hepatitis (AIH), also known as lupoid hepatitis, is a chronic progressive disease of unknown aetiology. First-line therapy consists of corticosteroids alone or in…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 848 • 2013 ACR/ARHP Annual Meeting
Human Papillomavirus Vaccine Uptake Among Children and Young Adults With Autoimmune Diseases
Candace H. Feldman¹, Linda T. Hiraki², Joyce Lii³ and Seoyoung C. Kim⁴, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoimmune diseases such as lupus and inflammatory bowel disease are associated with increased rates of human papillomavirus (HPV), the most common sexually transmitted disease…
Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
Lawrence McAdam¹, Michael Eberhardson², William Grainger³, Kim Papp⁴, Stephen Hall⁵, Tina Sterling⁶, Jon Stek⁶, Lei Pang⁶, Yanli Zhao⁶, Ivan Chan⁶, Richard Haupt⁶, Janie Parrino⁶ and Jeffrey Silber⁶, ¹Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, ²Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Neurological Physicians of Arizona, Gilbert, AZ, ⁴K. Papp Clinical Research,, Waterloo, ON, Canada, ⁵Emeritus Research, Malvern, Australia, ⁶Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…
Abstract Number: 1929 • 2012 ACR/ARHP Annual Meeting
Pernicious Anemia and Vitamin B-12 Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray
Michael R. Lovy, Desert Oasis Healthcare, Palm Springs, CA
Background/Purpose: The occurrence of multiple autoimmune disorders in individual patients is commonly observed. Rarely, this is explained by recently recognized genetically based autoimmune polyendocrine syndromes.…
Abstract Number: 338 • 2012 ACR/ARHP Annual Meeting
The Potent Phosphoinositide-3-Kinase-(δ,γ) Inhibitor IPI-145 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects
James R. Porter¹, Janid Ali², Jonathan P. DiNitto², Joi Dunbar², Kerrie Faia², Jennifer Hoyt², Brianne Leary², Alice R. Lim², Christian Martin², Charlotte McKee², Patrick O'Hearn², Melissa Pink², Jennifer Proctor², John Soglia², Bonnie Tillotson², Kerry White², David G. Winkler² and Vito J. Palombella², ¹Product Development, Infinity Pharmaceuticals, Inc., Cambridge, MA, ²Infinity Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Phosphoinositide-3-kinases (PI3K) play pivotal roles in cell signaling and regulate a variety of cellular functions. PI3K-δ and PI3K-γ isoforms are necessary for adaptive and…
Abstract Number: 1820 • 2012 ACR/ARHP Annual Meeting
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil^®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System
Lamiae Grimaldi-Bensouda¹, Michel Rossignol², Elodie Aubrun¹, Pamela Leighton³, Didier Guillemot⁴, Alfred Mahr⁵, Jacques Benichou⁶, Paul-Henri Lambert⁷, Bertrand Godeau⁸ and Lucien Abenhaim⁹, ¹LA-SER, Paris, France, ²LA-SER, Centre for Risk Research, Montreal, Canada, ³LA-SER Europe Ltd., London, United Kingdom, ⁴Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, ⁵Internal Medicine, Hospital Saint-Louis, Paris, France, ⁶INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, ⁷Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, ⁸Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁹LA-SER Europe Ltd, London, United Kingdom
Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.